US 9938272
Hydrazine compound as blood coagulation factor Xa inhibitor
granted A61KA61K31/437A61P
Quick answer
US patent 9938272 (Hydrazine compound as blood coagulation factor Xa inhibitor) held by North China Pharmaceutical Company., Ltd. expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- North China Pharmaceutical Company., Ltd.
- Grant date
- Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K31/437, A61P, A61P7/02, A61P9/00